tiprankstipranks
Trending News
More News >
Estrella Immunopharma (ESLA)
NASDAQ:ESLA
US Market

Estrella Immunopharma (ESLA) Income Statement

Compare
25 Followers

Estrella Immunopharma Income Statement

Last quarter (Q1 2024), Estrella Immunopharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q1, Estrella Immunopharma's net income was $-3.38M. See Estrella Immunopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 24Dec 22Jun 22Jun 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 7.31M$ 1.57M$ 1.69M$ 733.69K
Depreciation and Amortization
$ 0.00$ 228.49K$ 236.56K$ 206.30K
EBITDA
$ -7.31M$ -915.46K$ -247.72K$ -733.69K
Operating Income
$ -7.31M$ -1.57M$ -1.69M$ -733.69K
Other Income/Expenses
$ 0.00$ 654.07K$ 1.44M$ 0.00
Pretax Income
$ -7.31M$ -915.46K$ -1.69M$ -733.69K
Net Income
$ -7.31M$ -996.10K$ -1.69M$ -733.69K
Per Share Metrics
Basic EPS
$ -0.21$ -0.17$ -0.29$ -0.02
Diluted EPS
$ -0.21$ -0.17$ -0.29$ -0.02
Weighted Average Shares Outstanding
35.20M 5.76M 5.85M 35.20M
Weighted Average Shares Outstanding (Diluted)
35.20M 5.76M 5.85M 35.20M
Currency in USD

Estrella Immunopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis